Abdelhady Khaled, Gramling-Babb Patricia, Awad Sawsan, Rebeiz Abdallah G, Salehi Payam, Chaudhry Ahmad, Diodato Michael, Rizkallah Lona Ernst, Chedrawy Edgar G, Prasad Sunil, Massad Malek G
Division of Cardiothoracic Surgery, University of Illinois at Chicago, 840 S Wood St, CSB 417 (MC 958), Chicago, IL 60612, USA.
Expert Rev Cardiovasc Ther. 2010 Feb;8(2):241-50. doi: 10.1586/erc.10.2.
Pulmonary hypertension (PH) is a devastating condition that without proper management can deteriorate progressively. Elevated pulmonary artery pressure without an identifiable etiology is called IPAH. PH resulting from a specific disease is referred to as secondary PH; left-sided cardiac disease can lead to an increase in pulmonary artery pressure resulting in increased vascular resistance and subsequent structural remodeling. If left-sided failure progresses to right-sided failure with high pulmonary artery pressure, the outcome is ominous. It has been clearly proven that early diagnosis and effective medical therapy can markedly decrease morbidity and mortality. In this review, we discuss the current treatment modalities and their limitations for PH secondary to heart failure. Conventional therapy in patients with pulmonary arterial hypertension as well as recent advances in the medical management of PH in general, are also described. Last, the surgical management of these patients and other promising interventional modalities are reviewed.
肺动脉高压(PH)是一种严重的疾病,若未得到妥善管理,病情会逐渐恶化。没有可识别病因的肺动脉压力升高被称为特发性肺动脉高压(IPAH)。由特定疾病导致的PH被称为继发性PH;左侧心脏病可导致肺动脉压力升高,进而导致血管阻力增加和随后的结构重塑。如果左侧心力衰竭进展为伴有高肺动脉压力的右侧心力衰竭,预后将很不乐观。已经明确证实,早期诊断和有效的药物治疗可显著降低发病率和死亡率。在本综述中,我们讨论了心力衰竭继发性PH的当前治疗方式及其局限性。还描述了肺动脉高压患者的传统治疗方法以及PH总体药物管理的最新进展。最后,对这些患者的手术管理和其他有前景的介入方式进行了综述。